Snoop Dogg’s Death Row Cannabis Enters Ohio Market

COLUMBUS – Death Row Records Cannabis, the Cannabis brand launched by rapper and entrepreneur Calvin Cordozar Broadus Jr., commonly known as Snoop Dogg, has expanded into Ohio through a partnership with Pure Ohio Wellness. This move brings the brand’s signature products to Ohio’s growing recreational Cannabis market, marking a significant step in its nationwide expansion.

The brand debuted in Ohio on August 10 at Pure Ohio Wellness dispensaries in Dayton and London, as well as at Story Cannabis in Cincinnati. The initial product offering includes a tenth-ounce package of the Apple Fritter strain. Additional flower varieties and branded merchandise are planned for release in the coming weeks.

Snoop Dogg, who acquired Death Row Records in 2022 and introduced its Cannabis line in 2023, linked the Ohio launch to his current tour schedule. “Ohio, get ready,” he said in a statement. “I’m bringin’ that Death Row energy to the stage and to your dispensaries.” The announcement coincides with his performance at a post-game concert in Cincinnati on August 11, following the Reds-Phillies game.

Pure Ohio Wellness, founded in 2018 and a holder of a top-tier cultivation license, emphasized the alignment of this partnership with its commitment to quality. “Death Row Cannabis honors the cultural heritage of hip-hop while delivering consistent, high-quality products,” said Larry Pegram, the company’s founder and chief executive.

This expansion positions Death Row Cannabis to capitalize on Ohio’s recreational market, which recorded over $100 million in sales in its first month after legalization in August 2024, per state regulatory data. Celebrity-driven brands like Death Row could gain a competitive edge through brand recognition, potentially driving revenue for dispensary partners in a market facing tight pricing dynamics. Additionally, the launch follows Ohio’s 2023 voter approval of recreational Cannabis, underscoring how high-profile figures can help normalize the industry in states shifting from medical-only frameworks.